The first 23 minutes of the video talked about the breathalyser and the work that has been done in it, as well as he questions from about 45 minutes onwards are also related. It describes the trials, the importance of the real world data collection vs clinical studies, and the operation of the device. At one points he says the artificial intelligence is the most important part of the device.

The middle section of the presentation talks about the skin tattoo Haick has invented, which will be useful for patients in rural areas to detect diseases such as Tuberculosis. It is very impressive and shows how brilliant Haick and his team are. The original tattoo they developed was able to self repair when completely cut and repaired itself within 24 hours, although it didn't work well in liquids. However, they decided this wasn't good enough and engineered a new polymer technology combined with a heating device capable of self-healing within 30 seconds, and capable of working in liquid and gaseous environments.
It goes to show just how incredible the work he is doing. It gives a lot of confidence about the other products he developed like Nanose. I think we have been very fortunate to have been partnered with him, and it will give a very strong example of beneficial AI on those who see and use Nanose.

It's also worth mentioning he said the data coming from the tattoo would have to link to a device through something such as RFID. So to analyse the results, another device is required, likely to do machine learning IMO. This to me indicates additional devices which could incorporate Akida technology.

For those that are interested, there was also a new article talking about the tattoo:
https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202100235

Profiles of Volatile Biomarkers Detect Tuberculosis from Skin

Abstract

Tuberculosis (TB) is an infectious disease that threatens >10 million people annually. Despite advances in TB diagnostics, patients continue to receive an insufficient diagnosis as TB symptoms are not specific. Many existing biodiagnostic tests are slow, have low clinical performance, and can be unsuitable for resource-limited settings. According to the World Health Organization (WHO), a rapid, sputum-free, and cost-effective triage test for real-time detection of TB is urgently needed. This article reports on a new diagnostic pathway enabling a noninvasive, fast, and highly accurate way of detecting TB. The approach relies on TB-specific volatile organic compounds (VOCs) that are detected and quantified from the skin headspace. A specifically designed nanomaterial-based sensors array translates these findings into a point-of-care diagnosis by discriminating between active pulmonary TB patients and controls with sensitivity above 90%. This fulfills the WHO's triage test requirements and poses the potential to become a TB triage test.

Pure speculation, DYOR